Analysts Project 97% Revenue Plunge, 61-Cent Loss for Lipocine Inc.
LPCN has more than doubled off its 52-week low of $2.52.
Summary
Analysts are projecting a severe financial downturn for Lipocine Inc., with expectations of a 96.7% decrease in quarterly revenue to $116 thousand and a loss of 61 cents per share for the period ending December 31, 2025. This substantial projected revenue decline is highly material for a company of Lipocine's market capitalization, indicating significant operational challenges. While these are estimates, such a drastic forecast could prompt traders to adjust positions ahead of the official earnings release, expected around March 11. This news adds to a narrative of recent financial activity, following the company's expansion of its At-The-Market offering to $50 million in late February.
At the time of this announcement, LPCN was trading at $8.13 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $45.1M. The 52-week trading range was $2.52 to $12.37. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.